Daratumumab (DARA) + lenalidomide, bortezomib, and dexamethasone (RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM): A post hoc analysis of sustained minimal residual disease (MRD) negativity from GRIFFIN.
暂无分享，去创建一个
A. Jakubowiak | Sharmila Patel | J. Laubach | P. Richardson | R. Orlowski | P. Voorhees | J. Kaufman | D. Sborov | A. Chari | N. Shah | R. Silbermann | H. Pei | B. Reeves | C. Rodriguez | N. Nathwani | N. Bumma | L. Anderson | T. Lin | L. Costa | A. Cortoos